Researchers have identified several gene expression signatures that predict a patient's sensitivity to adjuvant chemotherapy. A test based on the findings could help identify which patients will do well with current treatments, and which might benefit from entering a clinical trial.
The researchers found that treatment with lactate and ketones causes cancer cells to express gene profiles associated with “stemness.” They believe that these gene signatures could, in turn, predict poor clinical outcome in breast cancer patients.
Under the terms of the partnership, Samsung will provide samples from Korean patients. Pfizer, in turn, will conduct genomic profiling on the samples and analyze the data in order to link gene signatures to patient outcomes.